Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today results from the Phase III persevERA Breast Cancer study evaluating investigational giredestrant in combination ...
Xencor, a biotechnology company developing antibody treatments, said that it received a notice of termination from Genentech on Wednesday. Genentech terminated the agreement in its entirety for ...
Novartis and Genentech are suing a U.S. company and a Canadian pharmacy over the importation of a Canadian version of their allergy medicine.
Roche Group AG’s RHHBY obesity drug push faces stiff competition after Genentech, a unit of Roche, reported Phase 2 results showing up to 10.7% weight loss—below expectations and lagging leading ...
A handful of pharmas and celebrities are joining forces with the National Bleeding Disorders Foundation (NBDF) for a ...
– Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, Ocrevus, in ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary endpoint, showing clinically ...
WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental to the industry. But few are willing to say they may be willing to delay treatments for ...
Genentech is honing in on an aspect of the patient community that is too often overlooked — the role of caregivers in managing rare diseases. In a recently-released short film, Genentech tells the ...
Biotechnology company Genentech is expanding its local manufacturing capabilities with a $450 million investment in its Oceanside campus. Genentech was founded in 1976 and has been considered a ...
Following an extensive inspection, the Environmental Protection Agency fined Genentech more than $158,000 for hazardous waste violations at a facility in California, the latest instance in which a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results